Conclusion

Unfortunately, the treatment of patients with relapsed or refractory ALL remains a daunting challenge to investigators and treating physicians. Hopefully, as we gain more insight into the biology of this disease, we can improve not only upon the treatment of patients who have relapsed, but also on initial treatment strategies, thereby minimizing those who require treatment in the relapsed setting. In addition, as we develop better techniques to assess for minimal residual disease, perhaps allowing for earlier intervention before overt clinical relapse, we may improve the outcome of these patients. Currently, the best chance for patients with relapsed disease is to induce a second CR (for suitable

0 0

Post a comment